IP Group (IPO) H1 2024 earnings summary

Executive summary

• Portfolio maturity is reflected in accelerated exits, successful funding rounds, and clinical progress, with H1 2024 cash realizations already surpassing full-year totals for 2022 and 2023, including the £30m Garrison sale and Hysata's $111m Series B.

• Capital returns to shareholders continue, with £20m in buybacks completed and a further £10m announced, despite a 9% NAV per share decline in H1, mainly due to Oxford Nanopore's share price drop.

• Portfolio companies raised £380m in H1 2024, up from £299m in H1 2023, maintaining a strong balance sheet with gross cash rising to £183.7m post-Garrison exit.

• Four therapeutics companies reported positive clinical trial data in H1 2024.

• Positive momentum is building for H2 and 2025, with further exits and milestones expected, and recovery in key holdings like Nanopore.

Financial highlights

• NAV per share declined 9% to 104.7p in H1 2024, with a £109.9m loss mainly from a £94.9m valuation drop in Oxford Nanopore.

• Gross cash at period end was £161.3m, rising to £183.7m post-Garrison exit; net assets declined by £110m.

• Net overheads reduced by 16% to £8.7m, with a targeted 25% annualized reduction by year-end.

• Portfolio investment of £49.1m across 23 companies; cash proceeds from exits were £3.4m in H1, with £41.2m received post-period end.

• £95m returned to shareholders since CEO tenure began, with buybacks retiring about 4% of share capital.

Outlook and guidance

• Strong pipeline of exits expected through 2025, with transactions anticipated at or above 2023 carrying values and several at advanced negotiation stages.

• Expects double-digit NAV per share returns in the near term, above the historical 7-8% average.

• Only 2% of larger portfolio companies need to raise funds before end of 2024; 34% funded to expected profitability.

• Hysata's first commercial units expected from 2026, with peak CapEx over the next few years.

• Focus on cost reduction, targeting over 25% reduction in net overheads on an annualized basis by year-end.